Genmab to Present at Lehman Brothers Tenth Annual Global Healthcare Conference

Summary: Genmab's CEO will present at the Lehman Brothers Tenth Annual Global   
Healthcare Conference in Miami, Florida on March 21, 2007.                      

Copenhagen, Denmark; March 19, 2007 - Genmab A/S (CSE: GEN) announced today its 
CEO, Lisa N. Drakeman, Ph.D., will present at the Lehman Brothers Tenth Annual  
Global Healthcare Conference in Miami on March 21 at 10:15AM local time.  The   
conference is being held March 19-21 at the Loews Miami Beach Hotel in Miami,   
Florida, USA.  The conference will feature presentations from nearly 200        
companies in the biotechnology and pharmaceutical industries.                   

Dr. Drakeman's presentation will be accessible via live and archived webcast at 
Genmab's website www.genmab.com.                                                

About Genmab A/S                                                                
Genmab A/S is a biotechnology company that creates and develops human antibodies
for the treatment of life-threatening and debilitating diseases. Genmab has     
numerous products in development to treat cancer, infectious disease, rheumatoid
arthritis and other inflammatory conditions, and intends to continue assembling 
a broad portfolio of new therapeutic products. At present, Genmab has multiple  
partnerships to gain access to disease targets and develop novel human          
antibodies including agreements with Roche and Amgen. A broad alliance provides 
Genmab with access to Medarex, Inc.'s array of proprietary technologies,        
including the UltiMAb(R) platform for the rapid creation and development of     
human antibodies to virtually any disease target. In addition, Genmab has       
developed UniBody(TM), a new proprietary technology that creates a stable,      
smaller antibody format.  Genmab has operations in Europe and the US. For more  
information about Genmab, visit www.genmab.com.                                 

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. Genmab is 
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to      
actual results, unless this is required by law.                                 

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-EGFr(TM); 
HuMax-Inflam(TM); HuMax-CD20(TM); HuMax-TAC(TM); HuMax-HepC(TM), HuMax-CD38(TM);
HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.                
UltiMAb(R) is a trademark of Medarex, Inc.                                      

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Investor News No. 03/2007